McKesson Corp. closed 6.64% below its 52-week high of $637.51, which the company achieved on August 2nd.

The stock's fall snapped a two-day winning streak.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson Amplify is intended to help protect critical pharmacy services and elevate the profession by strengthening the voice ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...

Brookstone Capital Management boosted its position in shares of McKesson Co. (NYSE:MCK – Free Report) by 42.8% in the fourth ...

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

The transaction enables McKesson to focus capital deployment and prioritize investments in strategic oncology and biopharma ...

McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Citi lowered the firm’s price target on McKesson (MCK) to $677 from $713 and keeps a Buy rating on the shares as part of a 2025 outcook for the ...

Beyond funding, McKesson Amplify also will provide resources, strategic support and other tools to help state pharmacy associations achieve their local and state advocacy goals in 2025.